甲状腺癌组织中DCBLD2和MAP4K3的表达及与临床病理特征及预后的关系  

Expression of DCBLD2 and MAP4K3 in Thyroid Cancer Tissue and Their Relationship with Clinico-pathological Features and Prognosis

作　　者：谈玖婷 傅聿明 刘婧 张倜然 TAN Jiuting;FU Yuming;LIU Jing;ZHANG Tiran(Xinghua People’s Hospital Affiliated to Yangzhou University,Jiangsu Xinghua 225700,China)

机构地区：[1]扬州大学附属兴化市人民医院,江苏兴化225700

出　　处：《现代检验医学杂志》2024年第2期34-38,67,共6页Journal of Modern Laboratory Medicine

基　　金：江苏省非编码RNA基础与临床转化重点实验室课题项目(202113):miR-451a通过PI3K/AKI/VEGF信号通路参与调控甲状腺细胞增殖的分子机制研究。

摘　　要：目的 探讨甲状腺癌组织中盘状蛋白含CUB和LCCL结构域2(discoidin CUB and LCCL domain containing 2,DCBLD2)、丝裂原活化蛋白激酶激酶激酶激酶3(mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3)的表达及与临床病理特征及预后的关系。方法 选取2016年1月~2020年6月在扬州大学附属兴化市人民医院诊治的92例甲状腺癌患者。采用免疫组织化学(immunohitochemistry,IHC)检测癌组织及癌旁组织中DCBLD2和MAP4K3的表达。比较不同临床病理特征甲状腺癌患者DCBLD2和MAP4K3表达差异。Kaplan-Meier曲线分析不同DCBLD2和MAP4K3表达患者无进展生存预后的差异。多因素COX分析影响甲状腺癌无进展生存预后的危险因素。结果 甲状腺癌组织中DCBLD2(67.39%),MAP4K3(65.22%)阳性率高于癌旁组织(5.43%,6.52%),差异具有统计学意义(χ^(2)=76.262,68.894,均P<0.05)。癌组织中DCBLD2与MAP4K3的表达呈显著正相关(r=0.742,P<0.05)。TNM分期Ⅲ~Ⅳ期、并发淋巴结转移癌组织中DCBLD2的阳性率(87.18%,93.75%)和MAP4K3的阳性率(84.62%,90.63%)分别高于Ⅰ~Ⅱ期(52.83%,50.94%)、无淋巴结转移癌组织(53.33%,51.67%),差异具有统计学意义(χ^(2)=11.230~15.513,均P<0.05)。DCBLD2阳性和阴性组患者三年无进展生存率分别为74.19%(46/62),93.33%(28/30)。MAP4K3阳性和阴性组患者三年无进展生存率分别为75.00%(45/60),90.63%(29/32)。DCBLD2阳性组,MAP4K3阳性组患者三年累积无进展生存率低于DCBLD2阴性组、MAP4K3阴性组,差异具有统计学意义(χ^(2)=4.533,4.138,P=0.033,0.046)。DCBLD2阳性(OR=1.659,P=0.001)、MAP4K3阳性(OR=1.606,P=0.001)、肿瘤TNM分期Ⅲ~Ⅳ期(OR=1.766,P=0.001)和并发淋巴结转移(OR=1.868,P=0.001)是影响甲状腺癌患者无进展生存预后的独立危险因素。结论 甲状腺癌组织中DCBLD2和MAP4K3表达升高,两者均参与甲状腺癌的发生发展,有助于评估甲状腺癌患者的无进展生存预后。Objective To investigate the expression of discoidin CUB and LCCL domain containing 2(DCBLD2)and mitogen activated protein kinase kinase kinase kinase 3(MAP4K3)in thyroid cancer and their relationship with clinico-pathological features and prognosis.Methods A total of 92 patients with thyroid cancer diagnosed and treated in Xinghua People’s Hospital Affiliated to Yangzhou University from January 2016 to June 2020 were selected.Immunohistochemistry(IHC)was used to detect the expression of DCBLD2 and MAP4K3 in thyroid cancer tissues and adjacent tissues.The expression differences of DCBLD2 and MAP4K3 in thyroid cancer patients with different clinicopathological features were compared.Kaplan-Meier curve analysis was used to analyze differences in the progression-free survival prognosis of patients with different DCBLD2 and MAP4K3 expressions.Multivariate COX analysis was used to analyze the risk factors affecting the progression-free survival prognosis of thyroid cancer.Results The positive rates of DCBLD2(67.39%)and MAP4K3(65.22%)in thyroid cancer tissues were higher than those in adjacent tissues(5.43%,6.52%),and the differences were statistically significant(χ^(2)=76.262,68.894,all P<0.05).The expression of DCBLD2 was positively correlated with MAP4K3(r=0.742,P<0.001).The positive rates of DCBLD2 and MAP4K3 in stage III~IV(87.18%,84.62%)and lymph node metastatic cancer tissues(93.75%,90.63%)were higher than those in stage I~II(52.83%,50.94%)and non lymph node metastatic cancer tissues(53.33%,51.67%),with statistically significant differences(χ^(2)=11.230~15.513,all P<0.05).The 3-year progression-free survival rates of DCBLD2-positive and DCBLD2-negative patients were 74.19%(46/62)and 93.33%(28/30),respectively.The 3-year progression-free survival rates of MAP4K3 positive and negative patients were 75.00%(45/60)and 90.63%(29/32),respectively.The 3-year cumulative progression-free survival rate of DCBLD2 positive group and MAP4K3 positive group was lower than that of DCBLD2 negative group and MAP4K3 negative gr

关 键 词：甲状腺癌 盘状蛋白含CUB和LCCL结构域2 丝裂原活化蛋白激酶激酶激酶激酶3 无进展生存预后 

分 类 号：R736.1[医药卫生—肿瘤] R730.43[医药卫生—临床医学]